Distributor inventory | Tablet
Sitagliptin 50 mg + Dapagliflozin 5 mg
Type 2 diabetes mellitus (as an add-on to diet and exercise) to improve glycaemic control when dual therapy is appropriate.
Sitagliptin is a DPP-4 inhibitor that increases incretin hormones, boosting insulin release and reducing glucagon in a glucose-dependent manner. Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys.
Oral tablet; take exactly as prescribed, usually once daily at the same time each day, with or without food. Maintain adequate hydration; follow diet/exercise plan and monitor blood glucose as advised.
Common side effects of SITENALI -D 50/5MG TAB may include:
Not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration/low blood pressure; maintain fluids especially in elderly or with diuretics. May cause genital/urinary infections; seek care for fever, burning urination, genital itching/discharge. Rare but serious: pancreatitis (severe abdominal pain), ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing), severe allergic reactions. Use caution in kidney impairment; dose/appropriateness depends on eGFR—periodic renal function monitoring needed. Stop and consult doctor before major surgery or during prolonged fasting/acute illness as advised.
